论文部分内容阅读
目的研究山莨菪碱对慢性肝炎血清肝纤维化相关指标的影响。方法将75例慢性肝炎患者随机分为两组。治疗组37例,对照组38例,均给予水飞蓟素、肝泰乐、甘草酸二胺等药物常规保肝治疗。治疗组加用山莨菪碱,20～40 mg/d,分2次静脉注射或静脉滴注。2个月后,对比两组治疗前、后的血清总胆红素(TBIL)、丙氨酸氨基转移酶(ALT)、胆碱酯酶(CHE)和血清肝纤维化指标的变化。结果治疗后两组肝功能均恢复良好,但治疗组血清肝纤雏化指标下降显著,两组对比差异有统计学意义(P<0.01)。结论山莨菪碱治疗慢性肝炎具有明显降低血清肝纤维化指标的作用,反映了山莨菪碱对肝纤维化发生的抑制作用。
Objective To study the effect of anisodamine on serum hepatic fibrosis related indicators in chronic hepatitis. Methods 75 patients with chronic hepatitis were randomly divided into two groups. The treatment group 37 cases, the control group 38 cases were given silymarin, liver Taili, glycyrrhizic acid and other drugs conventional liver protection treatment. Treatment group plus anisodamine, 20 ~ 40 mg / d, 2 times intravenous injection or intravenous drip. After 2 months, the changes of serum total bilirubin (TBIL), alanine aminotransferase (ALT), cholinesterase (CHE) and serum liver fibrosis were compared between the two groups before and after treatment. Results After treatment, the liver function of both groups recovered well, but the index of serum liver fibrosis decreased significantly in the treatment group, with significant difference between the two groups (P <0.01). Conclusion Anisodamine treatment of chronic hepatitis has a significant role in reducing serum hepatic fibrosis, reflecting the inhibitory effect of anisodamine on liver fibrosis.